2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
117
Triple Negative Breast Neoplasms
27
Neoplasm Metastasis
18
Sarcoma
17
Neoplasms
16
Carcinoma, Non-Small-Cell Lung
7
Ovarian Neoplasms
6
Brain Neoplasms
5
Prostatic Neoplasms
4
Urinary Bladder Neoplasms
3
Unspecified Adult Solid Tumor, Protocol Specific
3
Liposarcoma
3
Inflammatory Breast Neoplasms
3
HER2-negative Breast Cancer
3
Carcinoma, Transitional Cell
3
Urethral Neoplasms
2
Ureteral Neoplasms
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Recurrence
2
Pancreatic Neoplasms
2
Melanoma
2
Lymphoma
2
Lung Neoplasms
2
Leiomyosarcoma
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma
2
Advanced Breast Cancer
2
Interventions
Doxorubicin
3
pazopanib
2
Trabectedin
2
Ifosfamide
2
Dacarbazine
2
selinexor
1
repotrectinib
1
pembrolizumab
1
eribulin
1
Suspensions
1
Sunitinib
1
Proton Therapy
1
Nivolumab
1
Methotrexate
1
Magnetic Resonance Spectroscopy
1
Histamine H2 Antagonists
1
Fluorodeoxyglucose F18
1
Famotidine
1
FAPI-46
1
Epirubicin
1
Dasatinib
1
Cisplatin
1
Capsules
1
Axitinib
1
Angptl4 protein, mouse
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Solitary Fibrous Tumors
×
eribulin
×
Clear all
NCT03840772
2024-09-20
ERASING
Italian Sarcoma Group
Phase 2
Completed
16 enrolled